ESSA Pharma (EPIX) Stock Price, News & Analysis

Company Overview

ESSA Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies that target KCNQ potassium ion channels, which play a critical role in the regulation of neuronal excitability. The company’s research focuses on rare neurological and neurodevelopmental disorders driven by dysfunction in these channels. By leveraging proprietary small-molecule chemistry, ESSA Pharma aims to address underlying disease mechanisms rather than merely treating symptoms.

The company’s lead candidate, EPI-589, is an orally delivered small molecule designed to upregulate KCNQ channel activity. EPI-589 is currently being evaluated in clinical trials for Temple-Baraitser syndrome and KCNQ2 developmental and epileptic encephalopathy, two ultra-rare genetic conditions characterized by severe seizures, developmental delays and motor impairments. In addition to EPI-589, ESSA Pharma maintains a preclinical pipeline of novel modulators intended to expand its portfolio into other disorders linked to KCNQ dysfunction.

Founded in Canada and headquartered in Vancouver, ESSA Pharma conducts its research and clinical programs across North America and Europe. The company collaborates with leading academic institutions and patient advocacy groups to design trials that address the unique challenges of rare disease studies, including small patient populations and high unmet medical need.

ESSA Pharma is led by a management team with deep expertise in neuroscience drug development, translational research and regulatory strategy. The company is publicly traded on the Nasdaq Stock Market under the ticker symbol EPIX and is committed to advancing precision therapies that have the potential to transform outcomes for patients living with rare neurological disorders.

Key Stats

• Today's Range: $0.19 to $0.24
• 50-Day Range: $0.23 to $1.93
• 52-Week Range: $0.19 to $7.88
• Volume: 10.04 million shs
• Average Volume: 2.29 million shs
• Market Capitalization: $9.70 million
• P/E Ratio: N/A
• Dividend Yield: 824.39%
• Price Target: $2.00
• Consensus Rating: Hold

ESSA Pharma Stock Analysis - MarketRank™

ESSA Pharma scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

ESSA Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

ESSA Pharma has a consensus price target of $2.00, representing about 866.2% upside from its current price of $0.21.

Amount of Analyst Coverage

ESSA Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ESSA Pharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ESSA Pharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ESSA Pharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ESSA Pharma has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.03% of the outstanding shares of ESSA Pharma have been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ESSA Pharma has recently increased by 24.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

ESSA Pharma is a leading dividend payer. It pays a dividend yield of 713.82%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

ESSA Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.03% of the outstanding shares of ESSA Pharma have been sold short.

Short Interest Ratio / Days to Cover

ESSA Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ESSA Pharma has recently increased by 24.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for ESSA Pharma this week, compared to 6 articles on an average week.

Search Interest

5 people have searched for EPIX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added ESSA Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $293.00 in company stock.

Percentage Held by Insiders

15.50% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EPIX Stock Analysis - Frequently Asked Questions

How have EPIX shares performed this year?

ESSA Pharma's stock was trading at $1.79 at the beginning of 2025. Since then, EPIX stock has decreased by 88.4% and is now trading at $0.2070.

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) released its earnings results on Wednesday, August, 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08.

Who are ESSA Pharma's major shareholders?

ESSA Pharma's top institutional shareholders include Bank of America Corp DE (1.41%), DLD Asset Management LP (0.71%), BNP Paribas Financial Markets (0.61%) and LMR Partners LLP (0.45%). Insiders that own company stock include Bvf Partners L P/Il, David Ross Parkinson, Peter Virsik and Growth N V Biotech.
View institutional ownership trends.

How do I buy shares of ESSA Pharma?

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ESSA Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 8/13/2025
• Record date for 8/22 Dividend: 8/19/2025
• Dividend Payable: 8/22/2025
• Ex-Dividend for 8/22 Dividend: 8/25/2025
• Today: 9/10/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPIX
• CIK: 1633932
• Web: www.essapharma.com
• Phone: 778-331-0962
• Fax: 604-738-4080
• Employees: 50
• Year Founded: 2009

Price Target and Rating

• Average Price Target for ESSA Pharma: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +866.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.71%
• Return on Assets: -21.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 69.06
• Quick Ratio: 69.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 47,310,000
• Free Float: 39,975,000
• Market Cap: $9.79 million
• Optionable: Optionable
• Beta: 1.60